EGFR T790M mutation is a crucial gene alteration causing EGFR TKI resistance. However, the implication of T790M mutation is still unknown for the stepwise progression of EGFR TKI naïve lung adenocarcinoma. In this study, we studied site-related EGFR T790M mutation analysis in EGFR TKI naïve lung adenocarcinomas harboring double EGFR mutation (L858R and T790M or Exon 19 deletion (Del.19) and T790M) by droplet digital (dd) PCR method. We examined three resected lung adenocarcinoma cases harboring EGFR double mutation including T790M. These cases didn't receive EGFR TKI treatment. We divided formalin-fixed and paraffin embedded (FFPE) unstained slide tissues into 11-18 areas in each tumor and extracted DNAs from each area separately. The DNAs were analyzed by ddPCR. T790M mutation ratio (T790M/L858R or T790M/Del.19) were calculated. For three cases, we also performed EGFR FISH for analyzing EGFR copy number.In Case 2 and 3, T790M mutation ratio were 100% and 30% homogeneously and showed increased EGFR copy number also homogeneously. However, in case 1, it was different between invasive and non-invasive areas. EGFR copy number was also heterogeneous and showed increasing only in invasive area. We indicated a peculiar case harboring T790M heterogeneity and only invasive area had T790M mutation even though the case was not treated by EGFR TKI. It suggests that T790M is possibly significant not only for EGFR TKI resistance but also the progression in lung adenocarcinoma.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.prp.2018.05.016 | DOI Listing |
J Pathol
January 2025
Graduate Institute of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Ferroptosis has been characterised by disruption of the cell membrane through iron-related lipid peroxidation. However, regulation of iron homeostasis in lung cancer cells that are resistant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) remains unclear. Transcriptome analysis identified a significant downregulation of apoptosis-associated tyrosine kinase (AATK) mRNA expression in gefitinib-resistant PC9 (PC9-GR) cells, which were found to be more susceptible to ferroptosis inducers.
View Article and Find Full Text PDFRSC Med Chem
January 2025
Department of Chemistry, The State University of New York at Buffalo Natural Sciences Complex Buffalo NY 14260 USA
Small molecules targeting activating mutations within the epidermal growth factor receptor (EGFR) are efficacious anticancer agents, particularly in non-small cell lung cancer (NSCLC). Among these, lazertinib, a third-generation tyrosine kinase inhibitor (TKI), has recently gained FDA approval for use in combination with amivantamab, a dual EGFR/MET-targeting monoclonal antibody. This review delves into the discovery and development of lazertinib underscoring the improvements in medicinal chemistry properties, especially in comparison with osimertinib.
View Article and Find Full Text PDFJTO Clin Res Rep
February 2025
Department of Medicine, Division of Oncology, Stanford University, Stanford, California.
Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may have activity in mutated NSCLC that has progressed on TKI therapy alone. Therefore, we prospectively evaluated afatinib plus necitumumab in patients with mutated NSCLC.
View Article and Find Full Text PDFInt J Mol Sci
January 2025
Cancer Biotherapeutics Research Group, Life Sciences Institute, School of Biotechnology, Dublin City University, Dublin 9, D09 NR58 Dublin, Ireland.
HER2-positive/oestrogen receptor-positive (HER2+/ER+) represents a unique breast cancer subtype. The use of individual HER2- or ER-targeting agents can lead to the acquisition of therapeutic resistance due to compensatory receptor crosstalk. New drug combinations targeting HER2 and ER could improve outcomes for patients with HER2+/ER+ breast cancer.
View Article and Find Full Text PDFCancers (Basel)
January 2025
Department of Medical Oncology, Faculty of Medicine, İstinye University, İstanbul 34010, Turkey.
Background: Although higher-generation TKIs are associated with improved progression-free survival in advanced NSCLC patients with EGFR mutations, the optimal selection of TKI treatment remains uncertain. To address this gap, we developed a web application powered by a reinforcement learning (RL) algorithm to assist in guiding initial TKI treatment decisions.
Methods: Clinical and mutational data from advanced NSCLC patients were retrospectively collected from 14 medical centers.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!